Savara Inc
SVRANext catalyst
Molgramostim
Autoimmune pulmonary alveolar proteinosis
Get an email about SVRA's next catalysts
Track Savara (SVRA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 3 readout).See the timeline
3 upcoming, 0 past
SVRA Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.18 | FQ end Sep/2026 | Call: tbd
FDA PDUFA Date Molgramostim (MOLBREEVI)
For Autoimmune pulmonary alveolar proteinosis. BLA, Priority Review; extended from Aug 22 after a major amendment. Verified against the company announcement on 2026-10-16.
SourceMolgramostim Phase 3 Est. Readout
Estimated primary completion for Molgramostim trial (NCT06431776) in Autoimmune Pulmonary Alveolar Proteinosis. Topline data typically follows completion by weeks to months.
SourceUpcoming FDA decisions
Market Overview
Stock performance and key metrics
Molgramostim
Autoimmune Pulmonary Alveolar Proteinosis
Vancomycin inhalation powder
MRSA
Molgramostim Open-label
Autoimmune Pulmonary Alveolar Proteinosis
Inhaled molgramostim
Mycobacterium Infections, Nontuberculous
Vancomycin hydrochloride inhalation powder
Cystic Fibrosis
Antimycobacterial regimen
Mycobacterium Infections, Nontuberculous
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Molgramostim | Phase 3 | Autoimmune Pulmonary Alveolar Proteinosis | - | - |
Vancomycin inhalation powder | Phase 3 | MRSA | - | - |
Molgramostim Open-label | Phase 3 | Autoimmune Pulmonary Alveolar Proteinosis | - | - |
Inhaled molgramostim | Phase 2 | Mycobacterium Infections, Nontuberculous | - | - |
Vancomycin hydrochloride inhalation powder | Phase 2 | Cystic Fibrosis | - | - |
Antimycobacterial regimen | Phase 2 | Mycobacterium Infections, Nontuberculous | - | - |
Frequently asked questions
What is in Savara Inc's drug pipeline?→
CatalystAlert tracks 6 drug candidates in Savara Inc's (SVRA) pipeline across Phase 3, Phase 2. Its lead program is Molgramostim (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Savara Inc's next FDA catalyst?→
Savara Inc's (SVRA) next tracked catalyst is a PDUFA date expected Nov 22, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SVRA biotech catalysts?→
Add SVRA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Savara Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.